Esperion Therapeutics Inc (ESPR)
2.185
+0.09
(+4.30%)
USD |
NASDAQ |
May 10, 14:32
Esperion Therapeutics Enterprise Value: 576.14M for May 9, 2024
Enterprise Value Chart
Historical Enterprise Value Data
| Date | Value |
|---|---|
| May 09, 2024 | 576.14M |
| May 08, 2024 | 565.73M |
| May 07, 2024 | 628.23M |
| May 06, 2024 | 580.88M |
| May 03, 2024 | 573.30M |
| May 02, 2024 | 569.51M |
| May 01, 2024 | 565.73M |
| April 30, 2024 | 552.47M |
| April 29, 2024 | 556.26M |
| April 26, 2024 | 539.21M |
| April 25, 2024 | 556.26M |
| April 24, 2024 | 582.77M |
| April 23, 2024 | 575.20M |
| April 22, 2024 | 541.10M |
| April 19, 2024 | 548.68M |
| April 18, 2024 | 533.53M |
| April 17, 2024 | 527.85M |
| April 16, 2024 | 541.10M |
| April 15, 2024 | 545.84M |
| April 12, 2024 | 584.67M |
| April 11, 2024 | 616.86M |
| April 10, 2024 | 656.64M |
| April 09, 2024 | 707.78M |
| April 08, 2024 | 753.23M |
| April 05, 2024 | 793.01M |
| Date | Value |
|---|---|
| April 04, 2024 | 768.38M |
| April 03, 2024 | 770.28M |
| April 02, 2024 | 724.82M |
| April 01, 2024 | 707.78M |
| March 28, 2024 | 686.94M |
| March 27, 2024 | 675.58M |
| March 26, 2024 | 690.73M |
| March 25, 2024 | 664.19M |
| March 22, 2024 | 603.12M |
| March 21, 2024 | 569.81M |
| March 20, 2024 | 584.61M |
| March 19, 2024 | 564.26M |
| March 18, 2024 | 558.71M |
| March 15, 2024 | 562.41M |
| March 14, 2024 | 558.71M |
| March 13, 2024 | 584.61M |
| March 12, 2024 | 558.71M |
| March 11, 2024 | 571.66M |
| March 08, 2024 | 584.61M |
| March 07, 2024 | 601.27M |
| March 06, 2024 | 634.58M |
| March 05, 2024 | 623.47M |
| March 04, 2024 | 630.88M |
| March 01, 2024 | 651.23M |
| February 29, 2024 | 643.83M |
Enterprise Value Definition
EV is considered the theoretical purchase ("takeover") price of a business because a purchaser would take on the company's debt, while pocketing the company's cash and gaining a right to all of the company's future earnings.
Enterprise Value Range, Past 5 Years
202.67M
Minimum
Apr 25 2023
1.831B
Maximum
Feb 13 2020
611.05M
Average
571.81M
Median
Jan 13 2021
Enterprise Value Benchmarks
| United Therapeutics Corp | 9.690B |
| Dynavax Technologies Corp | 918.46M |
| Heron Therapeutics Inc | 535.31M |
| Aldeyra Therapeutics Inc | 116.85M |
| Deciphera Pharmaceuticals Inc | 1.744B |
Enterprise Value Related Metrics
| Net Income (Quarterly) | -56.34M |
| Revenue (Quarterly) | 32.25M |
| Total Expenses (Quarterly) | 74.62M |
| EPS Diluted (Quarterly) | -0.50 |
| Gross Profit Margin (Quarterly) | 64.49% |
| Profit Margin (Quarterly) | -174.7% |
| Earnings Yield | -97.03% |
| Normalized Earnings Yield | -97.03 |